Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (27,040)	$ (8,233)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Non-cash royalty revenue related to sale of future royalties	(14,752)	(16,753)
Non-cash interest expense on liability related to sale of future royalties	15,428	15,725
Stock-based compensation	14,499	12,647
Depreciation and amortization	9,109	9,733
Other non-cash transactions	(1,448)	313
Changes in operating assets and liabilities:
Accounts receivable, net	641	(43,845)
Inventory	2,600	1,757
Other assets	3,843	679
Accounts payable	(525)	(3,670)
Accrued compensation	7,056	(501)
Accrued clinical trial expenses	3,394	(7,262)
Other accrued expenses	949	1,667
Interest payable	(3,750)	(3,750)
Deferred revenue	(11,832)	1,480
Liability related to receipt of refundable milestone payment	0	(70,000)
Other liabilities	3,854	(7,366)
Net cash provided by (used in) operating activities	2,026	(117,379)
Cash flows from investing activities:
Maturities of investments	155,683	171,826
Purchases of investments	(202,870)	(200,160)
Sale of investments	23,778	21,661
Release of restricted cash	25,000	0
Purchases of property, plant and equipment	(8,722)	(6,090)
Net cash used in investing activities	(7,131)	(12,763)
Cash flows from financing activities:
Payment of capital lease obligations	(3,798)	(2,578)
Repayment of proceeds from sale of future royalties	0	(7,000)
Issuance of common stock, net of issuance costs	0	116,536
Proceeds from shares issued under equity compensation plans	15,516	16,168
Net cash provided by financing activities	11,718	123,126
Effect of exchange rates on cash and cash equivalents	(159)	(43)
Net increase (decrease) in cash and cash equivalents	6,454	(7,059)
Cash and cash equivalents at beginning of period	12,365	39,067
Cash and cash equivalents at end of period	18,819	32,008
Supplemental disclosure of cash flow information:
Cash paid for interest	16,095	16,487
Supplemental schedule of non-cash investing and financing activities:
Accrued debt issuance costs	$ 8,503	$ 0